Jul 292015

Family-owned construction firm recruits Chartered Director Paul Hooper-Keeley who brings more than 30 years of experience to the role

Chartered Director

Shaylor Group finance director Paul Hooper-Keeley (left) and chief executive Stephen Shaylor

Family-owned construction firm Shaylor Group has appointed Paul Hooper-Keeley as its new finance director.

Mr Hooper-Keeley is West Midlands chairman of the Chartered Institute of Management Accountants and brings with him more than 30 years' experience in both the public and private sectors.

He is also a Chartered Director and the current Institute of Director's West Midlands ambassador for their Chartered Director qualification.

Mr Hooper-Keeley has held finance director positions at board level for more 19 years and for the past 11 years has provided interim finance director services across the UK in all financial disciplines, along with strategic planning, leadership and team building skills.

He said: "I am delighted to be joining such a well-regarded business and I look forward to helping Shaylor Group maintain their momentum in becoming the pre-eminent name for quality construction projects throughout the UK."

Shaylor Group chief executive Stephen Shaylor added: "Paul's appointment comes at an exciting time for Shaylor Group, having recently secured a string of new high-profile contract awards and framework agreements.

"We are thrilled to welcome Paul into the business and I am personally looking forward to working closely with him to ensure our continued growth and success."

Jul 292015

Novogen appoints Chartered Director Iain Ross as acting CEO and re-appoints him to the Board

Iain RossSydney, July 22, 2015 - Novogen Limited (ASX:NRT; NASDAQ: NVGN), a US-Australian drug development company, today announced the appointment to the Board of Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive. Mr Ross, a former director of Novogen Limited will re-join the Board with immediate effect and take on the role of Acting Chief Executive until a permanent appointment is made.

Mr Ross is currently Chairman of Premier Veterinary Group PLC (formerly Ark Therapeutics PLC), a non-executive director of Amarantus Bioscience Holdings Inc and a non-executive director for ASX-listed companies Anatara Lifesciences Ltd, Benitec Biopharma Ltd and Tissue Therapies Ltd.

Following a career with multinational companies, Sandoz AG, Hoffman La Roche and Celltech Group plc, Mr Ross has over the past 20 years undertaken a number of company start-ups, turnarounds and exits as a Board member on behalf of private equity groups and banks. These include Quadrant Healthcare PLC (sold to Elan); Eden BioDesign (sold to Watson Pharmaceuticals); Phadia AB (sold to Cinven); SR Pharma PLC (merged with Atugen AG to form Silence Therapeutics PLC) Allergy Therapeutics Limited (prepared for IPO); and Ark Therapeutics PLC (subsidiaries sold off to private equity and a new business reversed in to form Premier Veterinary Group PLC).

Mr Ross brings to this role an impressive track record which includes multiple financing transactions, having raised more than £250m, both publicly and privately, as well as extensive experience in divestments and strategic restructures and more than 20 years in cross border management as a Chairman and CEO. He has led and participated in five IPOs on the London and Australian Stock Exchanges and two up-listings to NASDAQ, and has direct experience of M&A transactions in Europe, the US and Pacific Rim. He is a qualified Chartered Director and Vice Chairman of the Council of Royal Holloway, London University.

Jul 012015

Chartered Director Victoria Muir joined the Invesco Perpetual Select Trust Plc board on 1 July 2015

Victoria Muir

The Board of Invesco Perpetual Select Trust plc is pleased to announce the appointment of Ms Victoria Muir as a Non-Executive Director of the Company with effect from 1 July 2015.

Ms Muir is Global Head of Investor Relations at BlueBay Asset Management LLP, a Chartered Director and a Member of the Institute of Directors.  She was previously Head of Client Account Management at Royal London Asset Management Ltd, which position was the culmination of a twelve year progression in sales, marketing and client relationship related positions, and was also a director of a number of Royal London Group companies.

Invesco Perpetual is one of the largest independent investment managers in the UK

The other members of the board are:

Non-Executive Independent Chairman of the Board
Appointed 2006
Mr. Patrick A. F. Gifford is the Non-Executive Independent Chairman of the Board of Invesco Perpetual Select Trust Plc., since January 10, 2008. Gifford has served as a Director since the Company’s incorporation in August 2006. He is chairman of Martin Currie Pacific Trust plc and Murray Income Trust plc. He is also chairman of the supervisory committee of Scottish Life’s with-profits fund and an adviser to a pension fund. He was previously the chief executive of Fleming Investment Trust Management and a director of Robert Fleming Holdings.

Non-Executive Director
Appointed 2015

Non-Executive Independent Director
Appointed 2008
Sir Michael W. Bunbury is a Non-Executive Independent Director of Invesco Perpetual Select Trust plc., since 10 January 2008. A former chairman of Smith & Williamson, he is now a consultant to the firm. He is chairman of JPMorgan Claverhouse Investment Trust plc, BH Global Ltd and HarbourVest Global Private Equity Ltd and a former director of Foreign & Colonial Investment Trust plc. He has other directorships of various property investment and development companies.
Senior Non-Executive Independent Director
Appointed 2008
Mr. Alan Henry Clifton is a Senior Non-Executive Independent Director of Invesco Perpetual Select Trust plc., since 10 January 2008. He is a former managing partner of the stockbrokers, Kitcat & Aitken, and from 1990 until 2001 was the managing director of Morley Fund Management (now Aviva Investors), the asset management arm of Aviva plc, the UK’s largest insurance group. He is now chairman of Schroder UK Growth Fund plc, JPMorgan Japanese Smaller Companies Trust plc and International Biotechnology Trust plc and is an independent director of a number of other investment companies both in the UK and abroad.

Non-Executive Independent Director
Appointed 2007

Mr. David Rosier is a Non-Executive Independent Director of Invesco Perpetual Select Trust plc., since 28 November 2007. Following his retirement from Merrill Lynch Investment Managers (previously Mercury Asset Management) in 2002, he was a founder partner of Thurleigh Investment Managers LLP of which he is chairman. He is also chairman of the Armed Forces Common Investment Fund, a commissioner and chairman of the investment committee of The Royal Hospital Chelsea and a trustee of the Nuffield Trust for the Forces of the Crown, The Battle of Britain Memorial Trust and 1st The Queen’s Dragoon Guards Heritage Trust. He is a Fellow of the Chartered Institute of Securities & Investment.


%d bloggers like this: